Oxeia Biopharmaceuticals Inc
www.oxeiabiopharma.comOxeia Biopharmaceuticals is a clinical-stage biotech company developing new, innovative therapeutics for mild traumatic brain injury (mTBI), known as concussion, and related neuro-metabolic dysfunction. The company has a drug, OXE103, that began a Phase 2 clinical trial in the fall of 2020. To date there are few other studies aimed at treating these patients.
Read more
Oxeia Biopharmaceuticals is a clinical-stage biotech company developing new, innovative therapeutics for mild traumatic brain injury (mTBI), known as concussion, and related neuro-metabolic dysfunction. The company has a drug, OXE103, that began a Phase 2 clinical trial in the fall of 2020. To date there are few other studies aimed at treating these patients.
Read more
Country
State
Massachusetts
City (Headquarters)
Boston
Industry
Employees
1-10
Founded
2014
Estimated Revenue
$1 to $1,000,000
Social
Employees statistics
View all employeesPotential Decision Makers
Co - Founder
Email ****** @****.comPhone (***) ****-****Director and Co - Founder
Email ****** @****.comPhone (***) ****-****Advisory Board Member and Seed Investor
Email ****** @****.comPhone (***) ****-****Angel Investor
Email ****** @****.comPhone (***) ****-****
Technologies
(9)
